Literature DB >> 9353306

Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation.

N Singh1, G Zanusso, S G Chen, H Fujioka, S Richardson, P Gambetti, R B Petersen.   

Abstract

Prion diseases are characterized by the conversion of the normal cellular prion protein (PrPC), a glycoprotein that is anchored to the cell membrane by a glycosylphosphatidylinositol moiety, into an isoform that is protease-resistant (PrPres) and pathogenic. In inherited prion diseases, mutations in the prion protein (PrPM) engender the conversion of PrPM into PrPres. We developed a cell model of Gerstmann-Sträussler-Scheinker disease, a neurodegenerative condition characterized by PrPM-containing amyloid deposits and neuronal loss, by expressing the Gerstmann-Sträussler-Scheinker haplotype Q217R-129V in human neuroblastoma cells. By comparison to PrPC, this genotype results in the following alterations of PrPM: 1) expression of an aberrant form lacking the glycosylphosphatidylinositol anchor, 2) increased aggregation and protease resistance, and 3) impaired transport to the cell surface. Most of these alterations are temperature-sensitive, indicating that they are due to misfolding of PrPM.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9353306     DOI: 10.1074/jbc.272.45.28461

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  The normal cellular prion protein (PrPc) is strongly expressed in bovine endocrine pancreas.

Authors:  W M Amselgruber; M Büttner; T Schlegel; M Schweiger; E Pfaff
Journal:  Histochem Cell Biol       Date:  2005-10-06       Impact factor: 4.304

2.  Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein.

Authors:  Max Nunziante; Kerstin Ackermann; Kim Dietrich; Hanna Wolf; Lars Gädtke; Sabine Gilch; Ina Vorberg; Martin Groschup; Hermann M Schätzl
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

3.  Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

Authors:  J P Morello; A Salahpour; A Laperrière; V Bernier; M F Arthus; M Lonergan; U Petäjä-Repo; S Angers; D Morin; D G Bichet; M Bouvier
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 4.  Cellular biology of prion diseases.

Authors:  D A Harris
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

5.  Mutant prion protein D202N associated with familial prion disease is retained in the endoplasmic reticulum and forms 'curly' intracellular aggregates.

Authors:  Yaping Gu; Susamma Verghese; Sharmila Bose; Maradumane Mohan; Neena Singh
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

Review 6.  The consequences of pathogenic mutations to the human prion protein.

Authors:  Marc W van der Kamp; Valerie Daggett
Journal:  Protein Eng Des Sel       Date:  2009-07-14       Impact factor: 1.650

7.  Paradoxical role of prion protein aggregates in redox-iron induced toxicity.

Authors:  Dola Das; Xiu Luo; Ajay Singh; Yaping Gu; Soumya Ghosh; Chinmay K Mukhopadhyay; Shu G Chen; Man-Sun Sy; Qingzhong Kong; Neena Singh
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

Review 8.  A pathogenetic classification of hereditary ataxias: is the time ripe?

Authors:  Giuseppe De Michele; Giovanni Coppola; Sergio Cocozza; Alessandro Filla
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

9.  Selective processing and metabolism of disease-causing mutant prion proteins.

Authors:  Aarthi Ashok; Ramanujan S Hegde
Journal:  PLoS Pathog       Date:  2009-06-19       Impact factor: 6.823

10.  Loss of anti-Bax function in Gerstmann-Sträussler-Scheinker syndrome-associated prion protein mutants.

Authors:  Julie Jodoin; Micheal Misiewicz; Priya Makhijani; Paresa N Giannopoulos; Jennifer Hammond; Cynthia G Goodyer; Andréa C LeBlanc
Journal:  PLoS One       Date:  2009-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.